BusinessOTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference ParticipantsBy Nasdaq OMXJan 11, 2018, 6:39 PM UTC
BusinessAdaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy CompanyBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessAdaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell DoseBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
